IP Library Granted Patent US 12703737
Granted Patent B2
US 12703737 · App. 17/925,551 · Granted Aug 11, 2026

Recombinant proteins based on fibrinogen

Inventors: Thomas Scheper (Hannover, DE); Iliyana Pepelanova (Hannover, DE); Pia Gellermann (Hannover, DE); Sabrina Grünert (Marklohe, DE)
Assignee: Sartorius Lab Instruments GmbH & Co. KG
C07K14/75C12N15/70A61K38/00C07K2319/21
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12703737
App. No.
17/925,551
Granted
Aug 11, 2026
Kind
B2
Abstract

The present invention relates to isolated, recombinant polypeptides comprising the gamma chain of fibrinogen and a His-Tag. The present invention further relates to nucleic acids encoding said polypeptides, vectors comprising said nucleic acids, host cells, preferably bacterial host cells, comprising said nucleic acids or vectors, biohybrid materials comprising conjugates comprising said polypeptides, uses of the above, and methods for producing said polypeptides.

Claims (25)

1 . An isolated, recombinant polypeptide, comprising

(i) the gamma chain of fibrinogen, and

(ii) a His-Tag;

wherein said polypeptide comprises

(a) the amino acid sequence according to SEQ ID NO:3, or

(b) an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 3 and having fibrinogen gamma chain activity and His-Tag functionality;

wherein fibrinogen gamma chain activity refers to the characteristic of having functional binding sites for integrins, leukocytes, platelets, fibroblasts, endothelial cells and/or fibroblast growth factor 2 (FGF-2).

2 . The isolated, recombinant polypeptide according to claim 1 , wherein said gamma chain of fibrinogen comprises binding sites for integrins, leukocytes, platelets, fibroblasts, endothelial cells and/or fibroblast growth factor 2 (FGF-2).

3 . The isolated, recombinant polypeptide according to claim 1 , wherein said gamma chain of fibrinogen comprises

(i) the amino acid sequence according to SEQ ID NO: 1, or

(ii) an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 1 and having fibrinogen gamma chain activity.

4 . The isolated, recombinant polypeptide according to claim 1 , wherein said His-Tag comprises

(i) the amino acid sequence according to SEQ ID NO: 2, or

(ii) an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 2 and having His-Tag functionality.

5 . A biohybrid material, comprising a conjugate comprising the polypeptide according to claim 1 and one or more moieties, selected from the group consisting of polyethylene glycol (PEG), PEG derivatives, PEG diacrylate (PEG-DA), poly(oligo (ethylene glycol) methyl ether methacrylate (POEGMA), poly(N-(2-hydroxypropyl)-methacrylamide) (PHPMA) and HPMA copolymers, poly(vinylpyrrolidone) (PVP), poly(ethyleneimine) (PEI), poly(acroloylmorpholine) (PAcM), poly(2-ethyl 2-oxazoline) (PEOZ), divinylethermaleic anhydride/acid copolymer (DIVEMA), poly(styrene-co-maleic acid/anhydride) (SMA), poly(vinyl alcohol) (PVA) and temperature-sensitive polymers including poloxamers, poly(N-isopropylacrylamide) (PNIPAM), poly(N,N-diethylacrylamide) (PDEAM), poly(methylvinylether) (PMVE), poly(N-vinylcaprolactam) (PNVC1), and mixtures thereof.

6 . The isolated, recombinant polypeptide according to claim 1 , wherein said polypeptide comprises the amino acid sequence according to SEQ ID NO:3.

7 . The isolated, recombinant polypeptide according to claim 1 , wherein said polypeptide comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO:3 and having fibrinogen gamma chain activity and His-Tag functionality.

8 . The isolated, recombinant polypeptide according to claim 3 , wherein said gamma chain of fibrinogen comprises the amino acid sequence according to SEQ ID NO: 1.

9 . The isolated, recombinant polypeptide according to claim 3 , wherein said gamma chain of fibrinogen comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 1 and having fibrinogen gamma chain activity.

10 . The isolated, recombinant polypeptide according to claim 4 , wherein said His-Tag comprises the amino acid sequence according to SEQ ID NO: 2.

11 . The isolated, recombinant polypeptide according to claim 4 , wherein said His-Tag comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 2 and having His-Tag functionality.

12 . The isolated, recombinant polypeptide according to claim 7 , wherein said polypeptide comprises an amino acid sequence having at least 96% sequence identity to SEQ ID NO:3 and having fibrinogen gamma chain activity and His-Tag functionality.

13 . The isolated, recombinant polypeptide according to claim 12 , wherein said polypeptide comprises an amino acid sequence having at least 97% sequence identity to SEQ ID NO:3 and having fibrinogen gamma chain activity and His-Tag functionality.

14 . The isolated, recombinant polypeptide according to claim 13 , wherein said polypeptide comprises an amino acid sequence having at least 98% sequence identity to SEQ ID NO:3 and having fibrinogen gamma chain activity and His-Tag functionality.

15 . The isolated, recombinant polypeptide according to claim 14 , wherein said polypeptide comprises an amino acid sequence having at least 99% sequence identity to SEQ ID NO:3 and having fibrinogen gamma chain activity and His-Tag functionality.